Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust reduced its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 41.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 207,035 shares of the company's stock after selling 145,145 shares during the period. Emerald Mutual Fund Advisers Trust owned 0.26% of Akero Therapeutics worth $8,381,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Akero Therapeutics during the 4th quarter worth approximately $41,000. Sterling Capital Management LLC increased its stake in Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after buying an additional 1,582 shares in the last quarter. Amalgamated Bank increased its stake in Akero Therapeutics by 19.0% during the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company's stock worth $104,000 after buying an additional 410 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Akero Therapeutics by 14.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company's stock worth $114,000 after buying an additional 338 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Akero Therapeutics during the 1st quarter worth approximately $120,000.

Insider Activity at Akero Therapeutics

In related news, insider Catriona Yale sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $39.30, for a total value of $393,000.00. Following the transaction, the insider directly owned 95,034 shares in the company, valued at approximately $3,734,836.20. This represents a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Cheng sold 37,837 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $54.05, for a total value of $2,045,089.85. Following the completion of the transaction, the chief executive officer owned 556,487 shares in the company, valued at $30,078,122.35. This represents a 6.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 241,229 shares of company stock worth $11,933,685. Insiders own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AKRO shares. Citigroup cut their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Bank of America upped their price target on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of "Buy" and an average target price of $82.50.

Akero Therapeutics Price Performance

Shares of AKRO stock traded down $0.43 during trading hours on Friday, reaching $51.57. The company had a trading volume of 618,863 shares, compared to its average volume of 1,055,188. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80. The stock has a fifty day moving average of $49.59 and a 200-day moving average of $43.50. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -26.45 and a beta of -0.15. Akero Therapeutics, Inc. has a 12-month low of $21.34 and a 12-month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. On average, equities analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.